$TMO · Thermo Fisher Scientific Inc.

Thermo Fisher Scientific reported its third quarter 2026 financial results for the period ended September 26, 2026. Revenue grew 9% to $12.14 billion, including 6% organic revenue growth. GAAP diluted earnings per share increased 9% to $4.64, while adjusted EPS increased 15% to $6.68. GAAP operating income rose 17% to $2.26 billion, with operating margin of 18.6%, up from 17.4% a year earlier. Adjusted operating income grew 15% to $2.97 billion, and adjusted operating margin expanded to 24.5% from 23.3%.

The company attributed the results to its growth strategy and PPI Business System. During the quarter, it launched several new products, including the Orbitrap Isora mass spectrometer, the EMPAD G2 electron detector, an FDA-cleared autoimmune test, and the Ion 560 Chip. It also announced a proteomics initiative with Mayo Clinic called Precure, opened an AI-Automation Innovation Center in South Korea and a distribution center in Kentucky, and completed the divestiture of its microbiology business.

Thermo Fisher stated that updated 2026 financial guidance would be provided during its earnings conference call on October 21, 2026. The filing did not include specific annual guidance figures.